NeoTYPE® Ovarian Tumor Profile

The NeoTYPE Ovarian Tumor Profile analyzes 68 biomarkers through a combination of next-generation sequencing (NGS), FISH, and IHC as listed below. Test orders include summary interpretation of all results to help guide treatment decisions. If global HER2 (Other) IHC w/Breast Scoring result is 2+, case will reflex to global HER2 (Other) FISH w/Breast Scoring unless reflex to tech-only FISH or reflex opt-out is requested. If Pan-TRK IHC is expressed or equivocal, reflex to either NTRK NGS Fusion Panel (Default) or NTRK 1-3 FISH Panel will be added. A microsatellite instability (MSI) NGS result of "indeterminate" will create a reflex to MSI by PCR as long as the tumor percentage is ≥40% and paired normal tissue is available.

NGS (59 genes + 2 biomarkers):
AKT1, ARID1A, ATM, ATR, BARD1, BRAF, BRCA1, BRCA2, BRIP1, CDK12, CDKN2A, CDKN2B, CHEK1, CHEK2, CTNNB1, EGFR, ERBB2, ERBB4, ESR1, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCL, FGFR1, FGFR2, FGFR3, FOXL2, HRAS, KIT, KRAS, MET, Microsatellite Instability (MSI), MLH1, MRE11A (MRE11), MSH2, MSH6, NBN, NF1, NRAS, PALB2, PIK3CA, POLE, PMS2, PTEN, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD54L, RB1, SMAD4, SMO, SRC, STK11, TERT Promoter, TP53, Tumor Mutation Burden (TMB)

FISH:
EGFR Amplification, MET, MYC, PTEN, RET (tech-only available)

IHC:
FOLR1 FDA, HER2 (Other) IHC w/Breast Scoring, PD-L1 22C3 FDA, Pan-TRK (tech-only available for HER2 and PD-L1, opt out available for FOLR1 and HER2).